Vanguard Group’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-2,716,901
| Closed | -$292M | – | 4590 |
|
|
2023
Q1 | $292M | Buy |
2,716,901
+860,646
| +46% | +$92.4M | 0.01% | 1235 |
|
|
2022
Q4 | $204M | Buy |
1,856,255
+294,649
| +19% | +$32.4M | 0.01% | 1419 |
|
|
2022
Q3 | $92.2M | Buy |
1,561,606
+328,397
| +27% | +$19.4M | ﹤0.01% | 1837 |
|
|
2022
Q2 | $34.8M | Buy |
1,233,209
+31,667
| +3% | +$894K | ﹤0.01% | 2367 |
|
|
2022
Q1 | $45.4M | Buy |
1,201,542
+8,700
| +0.7% | +$329K | ﹤0.01% | 2352 |
|
|
2021
Q4 | $47.2M | Buy |
1,192,842
+649,933
| +120% | +$25.7M | ﹤0.01% | 2386 |
|
|
2021
Q3 | $12.9M | Buy |
542,909
+3,548
| +0.7% | +$84.1K | ﹤0.01% | 3098 |
|
|
2021
Q2 | $13.2M | Buy |
539,361
+419,361
| +349% | +$10.3M | ﹤0.01% | 3062 |
|
|
2021
Q1 | $2.19M | Buy |
+120,000
| New | +$2.19M | ﹤0.01% | 3840 |
|